A number of investigations have noted that func tional biological assays for heparin are not always reliable and may not reflect the actual biochemical level of heparin in pa tients receiving anticoagulant therapy. This creates the possi bility that patients receiving anticoagulant treatment may have an excess or deficiency of circulating levels of heparin. To address this problem, we have developed a direct biochemical measurement of heparin. The heparin assay uses fluorophore assisted carbohydrate electrophoresis (FACE) to directly mea sure the predominate disaccharide of unfractionated heparin. In this study, unfractionated heparin was measured in vitro throughout a wide range of heparin concentrations in plasma. Seven in vivo pharmacokinetic studies in five normal subjects given 3,000 USP units of unfractionated heparin intravenously showed a three-phase elimination process with higher peak plasma levels and shorter elimination times than predicted from previous studies. At these doses, heparin is largely eliminated intact through urinary excretion. Body weight has a significant effect on heparin kinetics. When we compared the direct bio chemical assay with two biological clotting assays, we found the latter can overestimate biochemical heparin concentrations. The FACE assay, due to its sensitivity, is also able to measure circulating levels of endogenous heparin in plasma and urine. Direct heparin measurement using the FACE technique is prac tical and useful for studies of the correlation of biochemical and biological activities.
Rosenberg RDThe heparin-antithrombin system: a natural anticoagulant mechanism . In: Colman RW, Hirsh J, Marder VJ, et al., eds. Hemostasis and Thrombosis, Basic Principles and Clinical Practice . Philadelphia: J.B. Lippincott Company, 1987:1373.
2.
Hirsh J.Heparin. N Engl J Med1991;324:1565.
3.
Fareed J., Jeske W., Callas D., et al. Modulation of endothelium by heparin and related polyelectrolytes . Clin Appl Thromb Hemost1996;2:200.
4.
Collins R., Scrimgeour A., Yusuf S., et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med1988;318:1162.
5.
Basu D., Gallus A., Hirsh J., et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med1972;287:324.
6.
Hull RD, Raskob GE, Hirsh J., et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med1986;315: 1109.
7.
Brill-Edwards P., Ginsburg JS, Johnston M., et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med1993;119: 104.
8.
Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. Arch Intern Med1997;157:2317.
9.
Levine MN, Hirsh J., Landefeld S., et al. Hemorrhagic complications of anticoagulant treatment. Chest1992;102:352S.
10.
Kayser SRHeparin: mechanism of action. In: Herfindal ET, Gourley DR, eds. Textbook of Therapeutics: Drug and Disease Management. Baltimore: Williams & Wilkins, 1996:861.
11.
Hirsh J., Fuster V.Guide to anticoagulant therapy part 1: heparin. Circulation1994;89:1449.
12.
McEvoy GK, Litvak K., Welsch OH Jr. Coagulants and anticoagulants: heparin sodium. American Hospital Formulary Service, Bethesda, MD 1997:1089.
13.
Erdman SM, Rodvold KA, Friedenberg WRThromboembolic disorders: heparin. In: DiPrio JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach . Stamford, CT: Appleton & Lange , 1997:406.
14.
Shojania AM , Tetreault J., Turnbull G.The variations between heparin sensitivity of different lots of activated thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol1988;89:19.
15.
van den Besselaar AM, Meeuwisse-Braun J., Bertina RMMonitoring heparin therapy: Relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost1990;63:16.
16.
Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med1997;157: 2475.
17.
Hyers TM, Hull RD, Weg JGAntithrombotic therapy for venous thromboembolic disease. Chest1995;108(suppl):335S.
18.
Mesters RM, Mikoteit T., Schiller M., et al. Markers of coagulation activation for evaluation of the antithrombotic efficacy of heparin: a prospective study in acute deep venous thrombosis. Blood Coagul Fibrinolysis1995;6:665.
19.
Levine MN, Hirsh J., Gent M., et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med1994 ; 154:49.
20.
Guo YC, Conrad HEAnalysis of oligosaccharides from heparin by reversed-phase ion-pairing high-performance liquid chromatography. Anal Biochem1988;168:54.
21.
Chen W., Yang VCVersatile non-clotting-based heparin assay requiring no instrumentation . Clin Chem1991;37:832.
22.
Oreste P., Peruzzi M., Stella P.Micromethod for the determination of heparin in plasma after intravenous and subcutanenous administration. Anal Biochem1993;210:136.
23.
Silvestro L. , Lanzarotti E., Marchi E., et al. Human pharmacokinetics of glycosaminoglycans using deuterium-labeled and unlabeled substances: evidence for oral absorption . Semin Thromb Hemost1994;20:281.
24.
Torri G., Bisio A., Casu B., et al. Nuclear magnetic resonance analysis of human urine: influence of intravenous and oral administration of glycosaminoglycans. Semin Thromb Hemost1994;20:144.
25.
Ma SC, Yang VC, Fu B., et al. Electrochemical sensor for heparin: further characterization and bioanalytical applications. Anal Chem1993;65:2078.
26.
Lindahl U., Kusche M., Lidholt K., et al. Biosynthesis of heparin and heparan sulfate in heparin and related polysaccharides. In: Ofusi FA, Danishefsky I, Hirsh J, eds. New York: New York Academy of Sciences1998:36.
27.
Mielke CH, Starr CM, Dittman WA, et al. Direct biochemical measurement of plasma heparin levels in patients on anticoagulant therapy. Presented at the 36th Annual Meeting of the American Society of Hematology; December 4, 1994; Nashville, TN.
28.
Starr C., Masada RI, Hague C., et al. Fluorophore-assisted-carbohydrate-electrophoresis, FACE® in the separation, analysis and sequencing of carbohydrates. J Chromatogr1996;720:295.
29.
Klock JC, Starr CMThe different faces of disease. FACE® diagnosis of disease. In: Alavi A, Axford JS, eds. Glycoimmunology. New York: Plenum Press, 1995:13.
30.
Klock JC, Starr CM, Devereaux D., et al. Pharmacokinetics of heparin and low molecular weight heparin by direct biochemical measurement using FACE®. Proceedings of the First Internet Glycotechnology Conference, September 1995.
31.
Wachsman M. , Mielke CH, Hayes JA, et al. The use of time step simulations and difference equations (TSSADEQ) in modeling heparin kinetics based on a direct heparin assay. J Clin Phannacol1999; (submitted).
32.
deSwart Cam , Nijmeyer B., Roelofs Jmm, et al. Kinetics of intravenously administered heparin in normal humans. Blood1982; 60:1251.
33.
Bjornsson TO , Wolfram KM, Kitchell BBHeparin kinetics determined by three assay methods. Clin Pharmacol Ther1982;31:104.
34.
Nyman D., Thurnherr N., Duckert F.Heparin dosage in extracorporeal circulation and its neutralization . Thromb Diath Haemorrh1974;33:102.
35.
Whitfield LR , Schentag JJ, Levy G.Relationship between concentration and anticoagulant effect of heparin in plasma of hospitalized patients: magnitude and predictability of interindividual differences. Clin Pharmacol Ther1982;32:503.
36.
Bjornsson TD , Levy G.Pharmacokinetics of heparin I. Studies of dose dependence in rats. J Pharmacol Exp Ther1979;210:237.
37.
Bjornsson TD , Levy G.Pharmacokinetics of heparin II. Studies of time dependence in rats. J Pharmacol Exp Ther1979;210:243.
38.
Bjornsson TDDose-dependent decrease in heparin elimination . J Pharm Sci1982;71:1186.
39.
Boneau B., Caranobe C., Gabaig AM, et al. Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb Res1987;46:835.
40.
Greenberg PL , Negrin R., Rodgers GMHeparin. In: Melmon KL, Morrelli HF, Hoffman BB, et al., eds. Clinical Pharmacology Basic Principles in Therapeutics . New York: McGraw-Hill, 1992: 558.
41.
Wessler S., Gitel SNHeparin: new concepts relevant to clinical use. Blood1979;53:525.
42.
Hirsh J., vanAken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism . Circulation1976;53:691.
43.
Manson L., Weitz JT, Podor JT, et al. The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. J Lab Clin Med1997;130: 649.
44.
Ceustermans R., Hoylaerts M., DeMol M., et al. Preparation, characterization and turnover properties heparin-antithrombin III complexes stabilized by covalent bonds. J Biol Chem1982;257:3401.
45.
Jaques LBHeparin: An old drug with a new paradigm. Science1979;206:528.
46.
McAvoy TJThe biological half life of heparin. Clin Pharmacol Ther1979;25:372.
47.
Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: A randomized controlled trial. Ann Intern Med1993;119: 874.
48.
Hirsh J., Warkentin TE, Raschke R., et al. Heparin and low-molecular weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety . Chest1998;114:489S.
49.
deSwart CA, Nijmeyer B., Andersson LO, et al. Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans. Thromb Haemost1984;52:66.
50.
Broze GJ Jr, Girard TJ, Novotny WFRegulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry1990;29:7539.
51.
Rapaport SIThe extrinsic pathway inhibitor. A regulator of tissue-factor dependent blood coagulation. Thromb Haemost1991;66:6.
52.
Rapaport SI , Rao Lvm.The tissue factor pathway: how it has become a "prima ballerina". Thromb Haemost1995;74:7.
53.
Lindahl AK, Abildgaard U., Larsen ML, et al. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thromb Res1991; 62:607.
54.
Kristensen HI, Ostergaard PB, Nordfang O., et al. Effect of tissue factor inhibitor (TFPI) in the Heptest® assay and in amidolytic anti-factor Xa assay for LMW heparin. Thromb Haemost1992 ;68: 310.
55.
Metcalfe DDMastocytosis. In: Wyngaarden JB, Smith LH, Ben-nett JC, eds. Cecil Textbook of Medicine , 18th ed. Philadelphia: WB Saunders, 1988:1483.
56.
Majerus PW , Broze GJ Jr, Miletich JP, et al. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, Molinoff PB, et al., eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics . New York: McGraw-Hill, 1996:1343.
57.
Engelberg H.Endogenous heparin activity deficiency and atherosclerosis. State of the art review. Clin Appl Thromb Hemost1996; 2:83.
58.
Engelberg H.Plasma heparin levels in normal man: correlation with serum cholesterol and very low density lipoproteins. Circulation1961;23:573.
59.
Engelberg H.Update on the relation of heparin to atherosclerosis and its thrombotic complications. Semin Thromb Hemost1988;14: 88.
60.
Durrington PNHow HDL protects against atheroma. Lancet1993; 342:1315.
61.
Beg O., Meng MS, Skarlatos SL, et al. Lipoprotein lipaseBethesda: a single amino acid substitution (Ala-176 leads Thr) to abnormal heparin binding and to loss of enzyme activity. Proc Natl Acad Sci USA1990;87:3474.
62.
Cadroy Y., Pourrat J., Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res1991;63:385.
63.
Cavari S., Stramaccia L., Vannucchi S.Endogenous heparinasesensitive anticoagulant activity in human plasma . Thromb Res1992;67:157.
